Jump to content

Baxalta: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
added citation and related content
No edit summary
Line 25: Line 25:
In August 2015, [[Shire Plc]] made an unsolicited $30.6 billion stock offer for the company<ref>{{cite web|url=http://www.wsj.com/articles/shire-offers-to-buy-baxalta-for-30-billion-1438688992|title=Shire Makes Unsolicited $30 Billion Bid for Baxalta|author=Tess Stynes|date=4 August 2015|work=WSJ}}</ref><ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/shire-offers-30b-for-baxalta/81251589/|title=Shire Offers $30B for Baxalta|work=GEN}}</ref> sending the Baxalta share price up over 16%. Baxalta investors would be set to receive 0.1687 of Shire's [[American Depositary Receipt]]s for every share they hold, representing a premium of 36% when compared to the company's stock price as of August 3.<ref name="kevinmccoy,usatoday">{{cite web|url=http://www.usatoday.com/story/money/2015/08/04/shire-makes-30b-offer-baxalta/31095773/|title=Pharma mania: Shire offers $30B for Baxalta|author=Kevin McCoy, USA TODAY|date=4 August 2015|work=USA TODAY}}</ref> This deal would also be set to create the largest global biotech company focused solely on rare diseases.<ref name="kevinmccoy,usatoday"/>
In August 2015, [[Shire Plc]] made an unsolicited $30.6 billion stock offer for the company<ref>{{cite web|url=http://www.wsj.com/articles/shire-offers-to-buy-baxalta-for-30-billion-1438688992|title=Shire Makes Unsolicited $30 Billion Bid for Baxalta|author=Tess Stynes|date=4 August 2015|work=WSJ}}</ref><ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/shire-offers-30b-for-baxalta/81251589/|title=Shire Offers $30B for Baxalta|work=GEN}}</ref> sending the Baxalta share price up over 16%. Baxalta investors would be set to receive 0.1687 of Shire's [[American Depositary Receipt]]s for every share they hold, representing a premium of 36% when compared to the company's stock price as of August 3.<ref name="kevinmccoy,usatoday">{{cite web|url=http://www.usatoday.com/story/money/2015/08/04/shire-makes-30b-offer-baxalta/31095773/|title=Pharma mania: Shire offers $30B for Baxalta|author=Kevin McCoy, USA TODAY|date=4 August 2015|work=USA TODAY}}</ref> This deal would also be set to create the largest global biotech company focused solely on rare diseases.<ref name="kevinmccoy,usatoday"/>


In January 2016, after 6 months of negotiations, the company agreed to be acquired by Shire for $32 billion.<ref>http://www.genengnews.com/gen-news-highlights/shire-baxalta-tie-the-knot-in-32b-merger/81252213/</ref> Shareholders have approved of the transaction and the deal is planned to close on 3 June 2016.<ref>{{Cite news|url=http://seekingalpha.com/article/3978239-facebook-watching|title=Facebook Is Watching You|last=DeMuth, Jr.|first=Chris|date=27 May 2016|work=Seeking Alpha|at=Baxalta|access-date=2016-05-27|via=}}</ref> The deal was completed at the beginning of June 2016.
In January 2016, after 6 months of negotiations, the company agreed to be acquired by Shire for $32 billion.<ref>http://www.genengnews.com/gen-news-highlights/shire-baxalta-tie-the-knot-in-32b-merger/81252213/</ref> Shareholders have approved of the transaction and the deal is planned to close on 3 June 2016.<ref>{{Cite news|url=http://seekingalpha.com/article/3978239-facebook-watching|title=Facebook Is Watching You|last=DeMuth, Jr.|first=Chris|date=27 May 2016|work=Seeking Alpha|at=Baxalta|access-date=2016-05-27|via=}}</ref> The deal was completed on June 3rd 2016.


==Pipeline==
==Pipeline==

Revision as of 12:03, 21 June 2016

Baxalta
Company typeSubsidiary
IndustryBiotechnology
Founded2015
Spun off from Baxter International
FateAcquired by Shire
Headquarters
United States Edit this on Wikidata
ProductsHematology, Immunology, Pulmonology
Number of employees
16,000[1]
Websitewww.baxalta.com

Baxalta (Bax, taken from its former parent company and Alta taken from the Latin Altus which translates as 'high' or 'profound'[2]) was a biopharmaceutical company founded on 1 July 2015 after its parent company, Baxter International, spun off biopharmaceutical division.[1][3] with revenue of $6 billion.

Company History

Baxalta inherited all of its parent company's on-the-market treatments, focused on hemophilia, The company aims to launch 20 in-development projects by 2020, heaping $2.5 billion in annual sales. Before being spun off, Baxalta acquired SuppreMol (a German company) for US$225 million.[4] Baxalta also acquired the blockbuster leukemia drug Oncaspar from Sigma-Tau Finanziaria S.p.A. for US$900 million.[1][5]

In August 2015, Shire Plc made an unsolicited $30.6 billion stock offer for the company[6][7] sending the Baxalta share price up over 16%. Baxalta investors would be set to receive 0.1687 of Shire's American Depositary Receipts for every share they hold, representing a premium of 36% when compared to the company's stock price as of August 3.[8] This deal would also be set to create the largest global biotech company focused solely on rare diseases.[8]

In January 2016, after 6 months of negotiations, the company agreed to be acquired by Shire for $32 billion.[9] Shareholders have approved of the transaction and the deal is planned to close on 3 June 2016.[10] The deal was completed on June 3rd 2016.

Pipeline

Hematology
  • BAX 855 – long-acting pegylated full-length rFVIII[11] hemophilia A drug awaiting FDA approval in conjunction with Nektar Therapeutics.[12] It is also undergoing Phase II trials for sickle cell.[13]
  • BAX 111 – submitted as a recombinant von Willebrand factor treatment for von Willebrand disease, filed with the FDA in December 2014.[14] In August 2015, data was released and published in the journal Blood,[15] which indicated that 100 percent of the patients treated with BAX 111 were successful in the management of bleeding episodes.[16][17]
  • BAX 817 – Recombinant factor VIIa[13]
  • BAX 335 – FIX gene therapy in Phase II.[13]
  • BAX 930 – Recombinant ADAMTS13[13]
  • BAX 826 – Recombinant, extended half-life Factor VIII[13]
  • BAX 888 – Factor VIII gene therapy in Phase I trials.[13]
Immunology
Oncology
  • MM-398 – Co-developed with Merrimack Pharmaceuticals.[18] Undergoing EU reviews for post-Gemcitabine pancreatic cancer, in Phase III trials for gastric cancer[13] Currently undergoing priority review with the FDA[19] for a new drug application.[20][21]
  • Pacritinib – Phase III trials for Myelofibrosis, Phase I trials for Acute Myeloid Leukemia and pre-clinical for Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome and Polycythemia Vera.[13]
  • Rigosertib – Phase III trials for Myelodysplastic Syndrome.[13]
  • BAX 069 – also known as Imalumab, in Phase II trials for Malignant Ascites and Metastatic Colorectal cancer.[13]

References

  1. ^ a b c Ben Reynolds. "Baxalta: A Rare Undervalued Biopharmaceutical Company". cnafinance.com.
  2. ^ "An Error Occurred Setting Your User Cookie". future-science.com.
  3. ^ "Baxalta: Baxter's newly named biopharma spinout has had its ups and downs". FierceBiotech.
  4. ^ a b Staff (1 April 2015). "Baxter Acquires SuppreMol and Its Immunoregulatory Therapy Pipeline". News: Industry Watch. Genetic Engineering & Biotechnology News (Paper). 35 (7): 10.
  5. ^ "Baxter Expands Cancer Therapies With $900M Oncaspar Buy". law360.com.
  6. ^ Tess Stynes (4 August 2015). "Shire Makes Unsolicited $30 Billion Bid for Baxalta". WSJ.
  7. ^ "Shire Offers $30B for Baxalta". GEN.
  8. ^ a b Kevin McCoy, USA TODAY (4 August 2015). "Pharma mania: Shire offers $30B for Baxalta". USA TODAY.
  9. ^ http://www.genengnews.com/gen-news-highlights/shire-baxalta-tie-the-knot-in-32b-merger/81252213/
  10. ^ DeMuth, Jr., Chris (27 May 2016). "Facebook Is Watching You". Seeking Alpha. Baxalta. Retrieved 2016-05-27.
  11. ^ "Blood Journal - Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A". bloodjournal.org.
  12. ^ "Baxalta & Nektar Reveal Full Data from Hemophilia Study - Analyst Blog". NASDAQ.com. 17 July 2015.
  13. ^ a b c d e f g h i j k l m n o p "Pharmaceutical Development Pipeline - Baxalta". baxalta.com.
  14. ^ "Baxalta's first-of-its-kind bleeding drug lines up for FDA approval". FierceBiotech.
  15. ^ "Blood Journal - Hemostatic efficacy, safety and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease". bloodjournal.org.
  16. ^ "Blood Publishes Phase III Data on Baxalta's Investigational Treatment for Von Willebrand Disease, the Most Common Type of Inherited Bleeding Disorder". Yahoo Finance. 3 August 2015.
  17. ^ "Blood Publishes Phase III Data on Baxalta's Investigational Treatment for Von Willebrand Disease, the Most Common Type of Inherited Bleeding Disorder - Business Wire". businesswire.com. 3 August 2015.
  18. ^ "MM-398". merrimackpharma.com.
  19. ^ Merrimack Pharmaceuticals, Inc. (25 June 2015). "U.S. FDA Grants Priority Review for MM-398 New Drug... -- CAMBRIDGE, Mass. and DEERFIELD, Ill., June 25, 2015 /PRNewswire/ --". prnewswire.com.
  20. ^ "U.S. FDA Grants Priority Review for MM-398 New Drug Application". merrimackpharma.com.
  21. ^ "Oncology Times". LWW.
Stub icon

This corporation or company article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Baxalta&oldid=726318770"